A Director at Pluristem (PSTI) is Buying Shares

Today, a Director at Pluristem (PSTI), Isaac Braun, bought shares of PSTI for $35K.

Following this transaction Isaac Braun’s holding in the company was increased by 8.53% to a total of $368.4K. In addition to Isaac Braun, one other PSTI executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Pluristem’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $50K and GAAP net loss of $8.68 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $1.53 million. Currently, Pluristem has an average volume of 1.92M.

Starting in April 2018, PSTI received 21 Buy ratings in a row.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.